IndraLab

Statements


USP9X activates LNPEP. 2 / 2
| 2

reach
"In stage III and IV cases with detectable lesions, a response was observed in 61.3% (19/31) treated with CAP and in 10.5% (2/19) treated with FAM."

reach
"The 5-year survival rate was 61.6% for cases treated with CAP and 56.3% for cases treated with FAM."